JP4216905B2 - Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体 - Google Patents

Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体 Download PDF

Info

Publication number
JP4216905B2
JP4216905B2 JP50858598A JP50858598A JP4216905B2 JP 4216905 B2 JP4216905 B2 JP 4216905B2 JP 50858598 A JP50858598 A JP 50858598A JP 50858598 A JP50858598 A JP 50858598A JP 4216905 B2 JP4216905 B2 JP 4216905B2
Authority
JP
Japan
Prior art keywords
triazolo
pyridazine
ylmethoxy
methyl
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50858598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514169A (ja
Inventor
ブロートン，ハワード・バーフ
カーリング，ウイリアム・ロバート
カストロ，ピネイロ・ホセ・ルイス
ギブリン，アレクサンダー・リチヤード
メイデン，アンドリユー
ムーア，ケビン・ウイリアム
ラツセル，マイケル・ジエフリー
ストリート，レズリー・ジヨージフ
Original Assignee
メルク シヤープ エンド ドーム リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615645.0A external-priority patent/GB9615645D0/en
Priority claimed from GBGB9625397.6A external-priority patent/GB9625397D0/en
Priority claimed from GBGB9714420.8A external-priority patent/GB9714420D0/en
Application filed by メルク シヤープ エンド ドーム リミテツド filed Critical メルク シヤープ エンド ドーム リミテツド
Publication of JP2002514169A publication Critical patent/JP2002514169A/ja
Application granted granted Critical
Publication of JP4216905B2 publication Critical patent/JP4216905B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50858598A 1996-07-25 1997-07-17 Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体 Expired - Fee Related JP4216905B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9615645.0A GB9615645D0 (en) 1996-07-25 1996-07-25 Therapeutic agents
GB9615645.0 1996-07-25
GBGB9625397.6A GB9625397D0 (en) 1996-12-06 1996-12-06 Therapeutic agents
GB9625397.6 1996-12-06
GBGB9714420.8A GB9714420D0 (en) 1997-07-09 1997-07-09 Therapeutic agents
GB9714420.8 1997-07-09
PCT/GB1997/001946 WO1998004559A2 (en) 1996-07-25 1997-07-17 Substituted triazolo-pyridazine derivatives as ligands for gaba receptors

Publications (2)

Publication Number Publication Date
JP2002514169A JP2002514169A (ja) 2002-05-14
JP4216905B2 true JP4216905B2 (ja) 2009-01-28

Family

ID=27268403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50858598A Expired - Fee Related JP4216905B2 (ja) 1996-07-25 1997-07-17 Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体

Country Status (24)

Country Link
US (1) US6255305B1 (sk)
EP (1) EP0915875B1 (sk)
JP (1) JP4216905B2 (sk)
KR (1) KR20000029548A (sk)
CN (1) CN1251589A (sk)
AT (1) ATE236904T1 (sk)
AU (1) AU723098B2 (sk)
BG (1) BG103112A (sk)
BR (1) BR9710729A (sk)
CZ (1) CZ18199A3 (sk)
DE (1) DE69720732T2 (sk)
EA (1) EA002436B1 (sk)
EE (1) EE9900027A (sk)
ES (1) ES2194205T3 (sk)
HU (1) HUP0600527A2 (sk)
IL (1) IL127911A0 (sk)
IS (1) IS4949A (sk)
NO (1) NO990304L (sk)
NZ (1) NZ333768A (sk)
PL (1) PL331072A1 (sk)
SK (1) SK9399A3 (sk)
TR (1) TR199900047T2 (sk)
WO (1) WO1998004559A2 (sk)
YU (1) YU2899A (sk)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200975B1 (en) * 1997-05-08 2001-03-13 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as GABA alpha 5 ligands
GB9715977D0 (en) * 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
GB9718254D0 (en) 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
GB9726701D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
GB9726699D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
GB9726702D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
GB9723999D0 (en) 1997-11-13 1998-01-14 Merck Sharp & Dohme Therapeutic use
AU1041599A (en) * 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
US6110915A (en) * 1997-12-18 2000-08-29 Merck & Co., Inc. Antiemetic use of triazolo-pyridazine derivatives
JP2002509150A (ja) 1998-01-14 2002-03-26 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのトリアゾロピリダジン誘導体
GB9801210D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801234D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801202D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
NZ504870A (en) * 1998-01-21 2002-11-26 Merck Sharp & Dohme Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9801397D0 (en) 1998-01-22 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
EP1087968A1 (en) * 1998-06-16 2001-04-04 MERCK SHARP & DOHME LTD. Triazolo-pyridine derivatives as ligands for gaba receptors
GB9813006D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Therapeutic agents
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
CA2346659A1 (en) * 1998-10-06 2000-04-13 Michiyo Gyoten Condensed pyridazine compounds, their production and use
JP2002527519A (ja) * 1998-10-16 2002-08-27 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのピラゾロトリアジン誘導体
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB2345443A (en) * 1999-01-08 2000-07-12 Merck Sharp & Dohme Use of triazolo-pyridazines for treating premenstrual syndrome
US6500828B1 (en) 1999-01-27 2002-12-31 Merck Sharp & Dohme Ltd. Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
US6737242B1 (en) 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
GB9919957D0 (en) * 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
GB9921351D0 (en) * 1999-09-09 1999-11-10 Merck Sharp & Dohme Therapeutic agents
US6355638B1 (en) * 1999-11-25 2002-03-12 Merck Sharp & Dohme Ltd. Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929685D0 (en) * 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0000564D0 (en) * 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
CA2442264A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
GB0122696D0 (en) * 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20060142178A1 (en) * 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
ATE420867T1 (de) * 2002-08-13 2009-01-15 Merck Sharp & Dohme Phenylpyridazin derivative als liganden für gaba- rezeptoren
MXPA05006478A (es) * 2002-12-18 2005-09-08 Vertex Pharma Triazolopiridazinas como inhibidores de proteinas cinasas.
PL1697371T3 (pl) 2003-12-19 2007-09-28 Bristol Myers Squibb Co Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
CN101133057B (zh) 2004-09-02 2011-03-09 尼科梅德有限责任公司 三唑并酞嗪化合物
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
EP1836207B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8183381B2 (en) * 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009123537A1 (en) * 2008-04-04 2009-10-08 Forskarpatent I Syd Ab GABAa RECEPTOR MODULATORS
CA2735549A1 (en) 2008-08-29 2010-03-04 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US9682991B2 (en) 2009-12-31 2017-06-20 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
BR112015009649A2 (pt) * 2012-11-07 2017-07-04 Hoffmann La Roche composto de triazolo
EP3407886A1 (en) * 2016-01-27 2018-12-05 Universität Zürich Use of gabaa receptor modulators for treatment of itch
CN107344936B (zh) * 2016-05-06 2022-06-03 上海赛默罗生物科技有限公司 三唑哒嗪类衍生物、其制备方法、药物组合物和用途
CN107344938B (zh) * 2016-05-06 2022-05-06 上海赛默罗生物科技有限公司 吡唑-三嗪类衍生物、其制备方法、药物组合物和用途
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2019226820A1 (en) 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
WO2023150377A1 (en) * 2022-02-07 2023-08-10 The Regents Of The University Of Colorado, A Body Corporate Small molecule cxcr4 agonists, method of synthesis, and method of use
CN114591352B (zh) * 2022-05-11 2022-09-09 上海赛默罗生物科技有限公司 一种三唑并哒嗪类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080712A (en) * 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
PH21834A (en) * 1982-01-18 1988-03-17 Lepetit Spa New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives
US4487930A (en) 1982-09-07 1984-12-11 The Dow Chemical Company 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines
IT1194310B (it) 1983-07-12 1988-09-14 Lepetit Spa Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
FR2562071B1 (fr) * 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
GB9726702D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use

Also Published As

Publication number Publication date
BG103112A (en) 1999-09-30
IS4949A (is) 1999-01-19
JP2002514169A (ja) 2002-05-14
EP0915875A2 (en) 1999-05-19
PL331072A1 (en) 1999-06-21
NZ333768A (en) 2000-09-29
ES2194205T3 (es) 2003-11-16
IL127911A0 (en) 1999-11-30
SK9399A3 (en) 2000-04-10
CN1251589A (zh) 2000-04-26
EP0915875B1 (en) 2003-04-09
AU723098B2 (en) 2000-08-17
EE9900027A (et) 1999-08-16
NO990304D0 (no) 1999-01-22
EA002436B1 (ru) 2002-04-25
AU3553997A (en) 1998-02-20
WO1998004559A2 (en) 1998-02-05
ATE236904T1 (de) 2003-04-15
HUP0600527A2 (en) 2006-11-28
NO990304L (no) 1999-03-25
CZ18199A3 (cs) 1999-06-16
KR20000029548A (ko) 2000-05-25
EA199900164A1 (ru) 2000-04-24
US6255305B1 (en) 2001-07-03
TR199900047T2 (xx) 1999-03-22
BR9710729A (pt) 1999-08-17
YU2899A (sh) 2000-03-21
DE69720732T2 (de) 2004-01-29
DE69720732D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
JP4216905B2 (ja) Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
JP4302980B2 (ja) Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体
US6476030B1 (en) Pyrazolo-triazine derivatives as ligands for GABA receptors
JP4672820B2 (ja) ＧＡＢＡα５リガンドとしての置換１，２，４−トリアゾロ［３，４−ａ］フタラジン誘導体
KR101548443B1 (ko) 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
JP2009506004A (ja) ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
US6313125B1 (en) Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
WO2002081474A1 (en) Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype
JP2002501066A (ja) Ｇａｂａ受容体に対するリガンドとしてのトリアゾロ−ピリダジン誘導体
SK121498A3 (en) Quinoxalinediones, method and intermediates for their producing, use thereof and pharmaceutical compositions based thereupon
JP2003516989A (ja) Ｇａｂａ受容体リガンドとしてのピラゾロ−ピリジン誘導体
JP2002518391A (ja) Ｇａｂａ受容体のリガンドとしてのトリアゾロ−ピリジン誘導体
US6319924B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
US7381725B2 (en) Pyridazine derivatives as ligands for GABA receptors
US6297235B1 (en) Triazolopyridazine derivatives for treating anxiety and enhancing cognition
JP2003516994A (ja) 認知能力を向上させるための置換１，２，３−トリアゾロ［１，５−ａ］キナゾリン
CA2317484A1 (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
US6613766B1 (en) Pentaaza-cyclopental[a]naphthalene derivatives as ligands for GABAa α5 receptors
CA2260774C (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
JP2003514909A (ja) 認識能力増強用ピラゾロ〔１，５−ｄ〕〔１，２，４〕トリアジン
US6444666B1 (en) Triazolopyridazine Derivatives for treating anxiety and enhancing cognition
MXPA99000990A (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
HRP980035A2 (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081107

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111114

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111114

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121114

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121114

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131114

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees